Sekar Kathiresan, Verve Therapeutics CEO

Verve gets New Zealand clear­ance to test base edit­ing ther­a­py di­rect­ly in the hu­man body

Two years ago, In­tel­lia and Ed­i­tas Med­i­cine ven­tured in­to the field of sci­ence fic­tion when the biotechs di­rect­ly edit­ed genes in hu­mans.

Now, fol­low­ing be­hind those two com­pa­nies, which have re­port­ed lim­it­ed da­ta thus far, Verve Ther­a­peu­tics will be­come the third biotech to test its gene edit­ing tech­nol­o­gy in hu­mans. To­day, the com­pa­ny an­nounced that it re­ceived clear­ance from New Zealand reg­u­la­to­ry au­thor­i­ties to be­gin clin­i­cal tri­als for its gene edit­ing pro­gram for pa­tients with HeFH, a com­mon ge­net­ic dis­ease that caus­es high cho­les­terol.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.